Procept BioRobotics announces 12 scientific research presentations

PROCEPT BioRobotics announced that 12 abstracts highlighting its Aquablation therapy for the treatment of benign prostatic hyperplasia, BPH, will be presented at the American Urological Association, AUA, Annual Meeting in San Antonio, Texas, from May 3 – 6, 2024. “The growing body of real-world clinical evidence on Aquablation therapy is reflected by the extensive range of presentations being showcased at the AUA,” said Reza Zadno, CEO of PROCEPT BioRobotics. “Aquablation therapy, one of the fastest growing robotics platforms, is the only BPH treatment that offers significant durable symptom relief while preserving sexual function and continence across prostates of all shapes and sizes. The continued momentum and interest in Aquablation therapy are a testament to our unwavering commitment to advancing innovative, safe and effective treatment options for patients.”